[go: up one dir, main page]

AR033413A1 - Metodo de terapia de reemplazo hormonal y forma de administracion del mismo - Google Patents

Metodo de terapia de reemplazo hormonal y forma de administracion del mismo

Info

Publication number
AR033413A1
AR033413A1 ARP020100080A ARP020100080A AR033413A1 AR 033413 A1 AR033413 A1 AR 033413A1 AR P020100080 A ARP020100080 A AR P020100080A AR P020100080 A ARP020100080 A AR P020100080A AR 033413 A1 AR033413 A1 AR 033413A1
Authority
AR
Argentina
Prior art keywords
daily
administration
ingestion
units
during
Prior art date
Application number
ARP020100080A
Other languages
English (en)
Inventor
Kulmann Hermann Dr
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR033413A1 publication Critical patent/AR033413A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Método de terapia de reemplazo hormonal en la cual, por lo menos en la post menopausia establecida, se administra una unidad diaria de por lo menos un componente hormonal, es decir con al menos un estrogeno (E) y/o al menos un gestágeno (G), de forma permanente y continua todos los días que se caracteriza porque durante al menos un período de ingestion que precede a la administracion permanente de unidades diarias de hormona se contempla una pausa de ingestion (P) durante la cual no se puede administrar unidades diarias o placebos o bien, se puede administrar unidades diarias con contenido mucho menor de estrogeno y/o gestágeno que durante la administracion permanente de unidades diarias de hormona en la post menopausia establecida durante la o las fases de ingestion del período de ingestion precedente, así como una forma de administracion de la terapia hormonal.
ARP020100080A 2001-01-11 2002-01-11 Metodo de terapia de reemplazo hormonal y forma de administracion del mismo AR033413A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10100911A DE10100911A1 (de) 2001-01-11 2001-01-11 Verfahren zur Hormonersatztherapie und dessen Darreichungsform

Publications (1)

Publication Number Publication Date
AR033413A1 true AR033413A1 (es) 2003-12-17

Family

ID=7670195

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100080A AR033413A1 (es) 2001-01-11 2002-01-11 Metodo de terapia de reemplazo hormonal y forma de administracion del mismo

Country Status (21)

Country Link
US (1) US7871994B2 (es)
EP (1) EP1372665B1 (es)
JP (1) JP2004525883A (es)
AR (1) AR033413A1 (es)
AT (1) ATE348620T1 (es)
AU (1) AU2007202118A1 (es)
BR (1) BR0206361A (es)
CA (1) CA2433656A1 (es)
CY (1) CY1106374T1 (es)
DE (2) DE10100911A1 (es)
DK (1) DK1372665T3 (es)
ES (1) ES2278896T3 (es)
IL (1) IL156655A0 (es)
MX (1) MXPA03006157A (es)
NO (1) NO20033155L (es)
NZ (1) NZ539581A (es)
PE (1) PE20020795A1 (es)
PT (1) PT1372665E (es)
UY (1) UY27117A1 (es)
WO (1) WO2002055086A2 (es)
ZA (1) ZA200306120B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538342A (en) * 2002-08-28 2007-08-31 Robert Casper Estrogen replacement regimen
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
WO2004041289A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
DK1670440T3 (da) 2003-09-29 2014-07-07 Novo Nordisk As HRT formuleringer
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4405590C1 (de) 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonbehandlung
DE4405591C1 (de) 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonsubstitution
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19539233A1 (de) 1995-10-21 1997-04-24 Klaus Dr Med Umbreit Oral einzunehmendes ovulationshemmendes Mittel

Also Published As

Publication number Publication date
PT1372665E (pt) 2007-03-30
DE60216899D1 (de) 2007-02-01
EP1372665A2 (en) 2004-01-02
DK1372665T3 (da) 2007-04-30
NZ539581A (en) 2007-07-27
US20040106586A1 (en) 2004-06-03
AU2007202118A1 (en) 2007-05-31
PE20020795A1 (es) 2002-10-03
DE10100911A1 (de) 2002-08-01
MXPA03006157A (es) 2003-09-16
ZA200306120B (en) 2004-09-08
NO20033155D0 (no) 2003-07-10
CA2433656A1 (en) 2002-07-18
DE60216899T2 (de) 2007-10-25
CY1106374T1 (el) 2011-10-12
IL156655A0 (en) 2004-01-04
WO2002055086A3 (en) 2003-10-16
ES2278896T3 (es) 2007-08-16
ATE348620T1 (de) 2007-01-15
US7871994B2 (en) 2011-01-18
UY27117A1 (es) 2002-07-31
BR0206361A (pt) 2004-02-17
EP1372665B1 (en) 2006-12-20
WO2002055086A2 (en) 2002-07-18
JP2004525883A (ja) 2004-08-26
NO20033155L (no) 2003-09-10

Similar Documents

Publication Publication Date Title
AR024566A1 (es) Administracion de esteroides androgenicos no orales a mujeres
SE0202857D0 (sv) Method and compositions for preventing hormone induced adverse effects
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
NO20053051L (no) Tretthetsreduserende middel.
NO20022058L (no) Farmasöytiske sammensetninger
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
DK0998287T3 (da) Anvendelse af levobupivacain
NO20025893D0 (no) Veksthormon sekretagoga
BR0014312A (pt) Combinação de loteprednol e anti-histaminas
AR033413A1 (es) Metodo de terapia de reemplazo hormonal y forma de administracion del mismo
EA200301023A1 (ru) Заместительная терапия эстрогенами
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
DK1035859T3 (da) Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler
DK1175433T3 (da) Androgenglycosider og androgen aktivitet deraf
AR051931A1 (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes
NO20072893L (no) Fast, peroralt prevensjonsmiddel
AR034716A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
RU2000108520A (ru) Способ восстановительного лечения больных остеоартрозом
RU97109896A (ru) Способ лечения хронических одонтогенных гайморитов с ороантральным сообщением
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
BR0309621A (pt) Uso de estrógenos conjugados em combinação com trimegestona na terapia de substituição de hormÈnios
李景云 ACUPUNCTURE HAS EFFECTS OF ANTI-INFLAMMATION AND FEVER RELIEVING——A Tentative Idea of Conducting Acupuncture Instead of Prescribing Antibiotics
MD1780F1 (en) Method of treatment of patients with hepatic cirrhosis
Sung-Wan et al. Micro-domanial Interaction of Na+-Ca2+ Exchange with L-Type Ca~(2+) Channel in the Rat Ventricular Myocytes

Legal Events

Date Code Title Description
FB Suspension of granting procedure